Propulsid (cisapride) — the Heartburn Blockbuster Pulled in 2000 After 80 Arrhythmia Deaths

Summary

When Janssen Pharmaceutica — the Belgian unit of Johnson & Johnson — announced on 23 March 2000 that it would stop general U.S. marketing of Propulsid, it presented the move as a precaution; the documented record shows a drug the company's own labels had flagged as potentially lethal since 1995, kept on the open market for five more years while prescriptions ran past thirty million. Propulsid (cisapride) was a gastrointestinal prokinetic approved by the U.S. Food and Drug Administration in 1993 for nighttime heartburn from gastroesophageal reflux. It worked by speeding the gut, but it also blocked a cardiac potassium channel, prolonging the QT interval and, in vulnerable patients, triggering torsades de pointes — a chaotic ventricular arrhythmia that can stop the heart.

The gap between the indication and the harm was the whole tragedy. Cisapride was approved for adult reflux, but its danger concentrated in people who should never have received it: patients taking common interacting drugs — the macrolide antibiotics erythromycin and clarithromycin, the antifungals ketoconazole, itraconazole and fluconazole — that raised cisapride's blood levels, and patients with underlying cardiac or metabolic risk. By the FDA's accounting, of the 341 serious arrhythmias and 80 deaths reported through December 1999, roughly 85 percent occurred in patients with a recognized contraindication or risk factor. The drug was, in effect, safe in the population that did not need protecting and dangerous in the population that did.

The verdict is therefore plain at the outset: an approved, widely prescribed heartburn pill killed through interactions its manufacturer and the FDA had named in the label years before the withdrawal, and a meaningful share of the dead were infants and children who received it off-label for colic and reflux even though it was never approved for pediatric use. One observational study of roughly 58,000 premature infants found that about a fifth had been given cisapride.

What followed was a slow regulatory unwind and a mass-tort settlement. Janssen halted general sale effective 14 July 2000, retaining only a tightly controlled limited-access protocol; in 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims that the drug caused some 300 deaths and nearly 16,000 injuries. Propulsid became the textbook case of a "Dear Doctor" letter and a black box that did not change prescribing fast enough to stop the dying.

Timeline

1993-07

FDA approval and U.S. launch

Cisapride is approved and marketed in tablet form for nocturnal heartburn from GERD; a suspension follows in 1995. It is cleared for adults only.

1993-09 → 1996-04

Early torsades signal

Through MedWatch, the FDA receives reports of dozens of patients with torsades de pointes or prolonged QT while taking cisapride within the first three years on market.

1995

First black box warning

After reviewing torsades reports, the FDA adds a boxed warning contraindicating concurrent use with antifungals (ketoconazole, itraconazole, fluconazole) and macrolide antibiotics that raise cisapride levels.

1998-06

Strengthened warning and 'Dear Doctor' letter

The FDA and Janssen issue a widely publicized June 1998 label strengthening and prescriber letter; same-day co-dispensing with explicitly contraindicated drugs falls by roughly 58 percent — a decline, but far from elimination.

1999-03-19

Vanessa Young dies

A 15-year-old Canadian, prescribed cisapride for a minor digestive complaint, collapses in cardiac arrest — a death that would anchor the cross-border reckoning.

2000-01-24

Final FDA advisory

The FDA alerts U.S. physicians to continuing fatal arrhythmias and effectively designates cisapride a last-resort therapy requiring screening ECGs.

2000-03-23

Withdrawal announced

Janssen, in consultation with the FDA, announces it will stop general U.S. marketing of Propulsid.

2000-07-14

General sale ends

Marketing stops; the drug survives only under a limited-access investigational protocol for narrowly defined patients who have failed all alternatives.

2001

Tally formalized in the literature

Analyses confirm 341 serious cardiac arrhythmias and 80 deaths reported July 1993–December 1999, with roughly 85 percent of cases carrying a known risk factor.

2004-02

$90 million settlement

Johnson & Johnson agrees to pay up to $90 million to resolve claims that Propulsid caused about 300 deaths and nearly 16,000 injuries.

The Prokinetic Promise: A Heartburn Drug With a Cardiac Liability Built In

Propulsid solved a real annoyance. Reflux disease afflicts tens of millions, and cisapride attacked it from a novel angle: rather than suppressing acid, it stimulated the gut to empty faster, clearing the esophagus. On that mechanism Janssen built a franchise of more than thirty million U.S. prescriptions by the late 1990s. But the same molecule that hurried the bowel also blocked the hERG potassium channel that governs the heart's electrical reset; blocking it lengthens the QT interval, and a long-enough QT can degenerate into torsades de pointes and sudden death. This was not a flaw discovered late. It is an intrinsic, dose-dependent property of the compound, and the danger scaled with anything that raised cisapride's blood concentration. The approval was for a benign-sounding adult condition, but the cardiac liability traveled with every pill, waiting for the wrong co-prescription, the wrong metabolism, or the wrong patient.

The Warnings That Did Not Work: Five Years of Labels and a Body Count That Kept Rising

The signal arrived early and was acknowledged formally. By 1995 the FDA had added a boxed warning naming the antifungals and macrolide antibiotics that must never be combined with cisapride, because those drugs throttle the liver enzyme (CYP3A4) that clears it, sending blood levels — and QT intervals — climbing. In June 1998 the warning was strengthened and a "Dear Doctor" letter went to physicians. The interventions worked partially and insufficiently: contraindicated co-dispensing dropped by more than half, which means it persisted by nearly half, and prescriptions for the drug itself barely flinched. A boxed warning is a passive instrument that depends on a busy clinician reading it, remembering it at the point of prescribing, and reconciling it against every other drug and comorbidity the patient carries. For five years cisapride remained freely available while torsades reports accumulated, including in children given the drug off-label for colic and reflux — uses for which it was never approved and never adequately studied. The warnings changed the paperwork; they did not empty the morgue.

The Reckoning: A Quiet Withdrawal, a Teenage Death, and a $90 Million Settlement

The drug was pulled not by a single decisive trial but by an accumulating toll the labels could no longer absorb. On 24 January 2000 the FDA issued a final advisory reducing cisapride to a last-resort therapy; on 23 March 2000 Janssen announced it would stop general marketing, and on 14 July 2000 open sale ended, leaving only a restrictive limited-access protocol. The reckoning's human face came from across the border: 15-year-old Vanessa Young, prescribed cisapride for a minor complaint, died of cardiac arrest in March 1999, and the Canadian inquiry into her death — and the 2001 CMAJ editorial "Lessons from cisapride" — became a touchstone for how falsely reassuring patient information and lagging regulators let a known-lethal drug keep killing. In the United States, litigation consolidated into multidistrict proceedings, and in February 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims spanning roughly 300 deaths and nearly 16,000 injuries, with no admission of liability. The heartburn blockbuster was retired; the lesson about passive warnings was not.

Contributing Factors

01

An intrinsic cardiac liability approved for a benign indication

Cisapride's hERG-channel blockade and QT prolongation were properties of the molecule, not rare idiosyncrasies. Clearing it for ordinary adult heartburn placed a drug with a built-in arrhythmia risk into a vast, low-acuity population, guaranteeing that a small per-patient hazard multiplied across thirty million prescriptions would produce a large absolute body count.

02

Lethality routed through common, predictable drug interactions

The deaths clustered where cisapride met CYP3A4 inhibitors — erythromycin, clarithromycin, ketoconazole, itraconazole, fluconazole — that spiked its blood levels. These were not exotic combinations but everyday co-prescriptions. A drug whose danger depends on what else the patient is taking demands active interaction-blocking systems, not a paragraph in a label.

03

Reliance on passive warnings that prescribing did not follow

The 1995 black box and 1998 "Dear Doctor" letter cut contraindicated co-dispensing by little more than half and barely dented total use. The episode is a controlled demonstration that boxed warnings and physician letters are weak levers: they inform without constraining, and harm continues at the margin the warning fails to reach.

04

Off-label diffusion into an unstudied pediatric population

Approved for adults, cisapride was nonetheless given to infants and children for colic and reflux — including, in one cohort, about a fifth of 58,000 premature babies. Approval boundaries are porous; once a drug is on the shelf, it migrates to populations it was never tested in, where the harm is hardest to detect and hardest to consent to.

05

Regulatory incrementalism outpaced by exposure

The FDA's response unfolded as a five-year sequence of label edits and letters rather than a prompt restriction, while prescriptions kept flowing. Each interval of incremental action — 1995 to 1998 to 2000 — translated directly into additional exposed patients, and the cross-border lag (Health Canada trailing the FDA by months) compounded the toll abroad.

Aftermath

The material consequence was a quiet death of a brand and a modest settlement: Johnson & Johnson's 2004 agreement to pay up to $90 million covered claims tied to roughly 300 deaths and nearly 16,000 injuries, a sum many critics judged small against fatal arrhythmias in children and teenagers. Propulsid did not vanish entirely — it persisted under a limited-access protocol for the rare patient with no alternative — but as a mass-market product it was finished. The durable ripple ran through drug-safety thinking on both sides of the border: Vanessa Young's death drove a Canadian coronial inquest and a national conversation about patient-directed drug information, and the CMAJ editorial "Lessons from cisapride" became required reading on the gap between what labels say and what patients are told. More broadly, cisapride entered the canon of cases — alongside terfenadine and astemizole — that established QT prolongation and torsades as a class hazard regulators must screen for before approval, accelerating the modern requirement that new drugs undergo dedicated "thorough QT" studies. What remains is a byword. "Propulsid" is invoked whenever a drug's known, labeled, interaction-driven lethality is allowed to persist because the safety system relied on warnings a prescriber must read rather than barriers a prescriber cannot bypass — the proof that a black box on paper is not a stop sign in practice.

Lessons

Treat an intrinsic, mechanistic hazard as a population problem, not a labeling problem: when a molecule itself prolongs the QT interval, the question is not how to warn around the risk but whether the indication is benign enough to justify exposing millions to it at all.
When harm depends on drug interactions, build the interlock, not the leaflet: active, automated interaction-blocking at the point of dispensing stops what a contraindication paragraph cannot — count the contraindicated co-prescriptions that persist after every warning, because that residue is the body count.
Read a black box as evidence the drug is dangerous, not as a fix that makes it safe: if a warning is strong enough to forbid common combinations, ask why the drug is still on the open shelf, and measure the patients exposed during every year the answer is "incremental action."
Police the off-label drift before it reaches the most vulnerable: approval for adults is not a wall, and a drug will find its way to infants and children unless someone actively monitors and constrains the populations it was never tested in.
Watch the regulatory lag across borders: when one agency restricts a drug, every month another agency waits is a month of avoidable exposure — harmonize fast, because the molecule does not respect jurisdictions.

References

Pharmacotherapy Update: Cisapride Withdrawal Requires Alternative Therapy (May/June 2000) Cleveland Clinic
Lessons from cisapride (editorial, 2001) Canadian Medical Association Journal (CMAJ)
FDA tells doctors to use heartburn drug as last resort (news, Feb 2000) BMJ / PMC
Cisapride Monograph for Professionals Drugs.com
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and FDA regulatory actions American Journal of Gastroenterology (Wysowski et al., 2001;96:1698-1703)